SG Americas Securities
NPCE icon

SG Americas Securities’s Neuropace NPCE Stock Holding History

SG Americas Securities’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$153K Buy
11,640
+4,029
+53% +$60.4K ﹤0.01% 2765
2025
Q4 		$118K Buy
+7,611
New +$102K ﹤0.01% 3159
2023
Q2 		– Sell
-25,388
Closed -$118K – 2883
2023
Q1 		$118K Buy
+25,388
New +$97.2K ﹤0.01% 2810

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SG Americas Securities's NPCE Position: Q1 2026 in Review

SG Americas Securities increased its Neuropace (NPCE) stake by 53% in Q1 2026, buying an estimated $60.4K and bringing the position to 11,640 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #2765.

SG Americas Securities first reported a position in NPCE in Q1 2023 and has held it in 3 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • SG Americas Securities held 11,640 shares of Neuropace worth $153K as of Q1 2026.
  • SG Americas Securities bought 4,029 Neuropace shares in Q1 2026, an estimated $60.4K.
  • Neuropace made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2765 holding.
  • SG Americas Securities first reported a position in Neuropace in Q1 2023 and has held it in 3 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.